This blog is based on the analysis titled, “RNA Therapies in Rare Diseases,” authored by Frost & Sullivan’s growth expert, Isai Pratha Karthik, and lead analyst, Priyanka Jain, from the TechVision—Health & Wellness team.
Executive Summary
RNA therapies are gaining momentum as disease-modifying approaches for rare diseases, many of which have an underlying genetic cause and limited treatment options. Clinical progress and regulatory approvals across antisense oligonucleotide (ASO) and small interfering RNA (siRNA) platforms are strengthening confidence in RNA drug development. For biopharmaceutical companies, investors, and healthcare stakeholders, advances across RNA modalities are creating opportunities to address unmet needs and expand precision treatment for rare diseases.
What Are RNA Therapies for Rare Diseases?
RNA therapies are treatments designed to modify, replace, suppress, or regulate RNA involved in disease-causing biological processes. For rare diseases with a genetic basis, these approaches can target underlying disease mechanisms rather than focusing primarily on symptom management.
Key RNA modalities include:
- Antisense oligonucleotides (ASOs): Modify RNA processing or reduce the production of disease-associated proteins
- Small interfering RNA (siRNA): Silence specific genes by targeting messenger RNA for degradation
- Messenger RNA (mRNA): Provides genetic instructions that enable cells to produce therapeutic proteins
Approvals such as nusinersen for spinal muscular atrophy, patisiran for hereditary transthyretin-mediated amyloidosis, givosiran for acute hepatic porphyria, and tofersen for SOD1-associated amyotrophic lateral sclerosis demonstrate the clinical potential of RNA-based approaches across rare diseases.
According to Frost & Sullivan, continued validation of RNA modalities is strengthening their potential as an important therapeutic approach for genetically driven rare diseases.
Why Are RNA Therapies Gaining Momentum in Rare Diseases?
Rare diseases continue to present a significant healthcare challenge, with many patients facing limited treatment options that primarily manage symptoms rather than modify the underlying disease. Because genetic abnormalities are responsible for many rare diseases, RNA therapeutics provide an opportunity to intervene closer to the biological source of disease.
Over the past decade, RNA therapies have progressed from largely experimental approaches toward validated therapeutic platforms. Regulatory approvals, expanding clinical pipelines, and advances in RNA design and delivery are supporting this transition.
Several developments are accelerating progress:
- Growing demand for disease-modifying treatments for rare diseases
- Clinical validation of ASO and siRNA platforms
- Expanding development across multiple RNA modalities
- Advances in targeted delivery and RNA engineering
- Increasing confidence following successful regulatory approvals
- Greater focus on genetically defined patient populations and precision therapeutics
What Will You Discover?
- RNA modalities advancing disease-modifying treatment for rare diseases
- Clinical development and innovation across ASO, siRNA, and mRNA therapies
- Growth opportunities shaping the future of RNA therapeutics for genetically driven rare diseases
Access the Sample Analysis on RNA Therapies in Rare Diseases
The next phase of development will depend on how effectively innovators can translate advances across RNA modalities into safe, targeted, and scalable treatments for underserved rare disease populations.
Which RNA modalities will unlock the next wave of rare disease treatment innovation?
Listen to the Growth Podcast to explore how RNA therapeutics
Strategic Imperatives Shaping RNA Therapies for Rare Diseases
RNA therapeutics are gaining strategic importance as high unmet need, new development models, and increasing competition reshape the rare disease landscape.
- Disruptive Technologies: More than 7,000 rare diseases have been identified, yet fewer than 5% have regulatory-approved treatments. Many patients continue to rely primarily on symptomatic care, creating significant demand for disease-modifying approaches. RNA technologies can address underlying genetic mechanisms, creating opportunities to expand treatment across underserved rare disease populations.
- Innovative Business Models: Growing demand for RNA therapies is encouraging companies to adopt more collaborative and flexible development models. Strategic partnerships, licensing arrangements, platform collaborations, and external innovation can help organizations access specialized RNA capabilities, accelerate development, and expand into additional rare disease indications.
- Competitive Intensity: The growing potential of RNA therapeutics is attracting start-ups and established biopharmaceutical companies developing differentiated RNA platforms. Emerging innovators are increasing competition across modalities and therapeutic areas, pushing companies to strengthen pipelines, differentiate technology platforms, and accelerate clinical development.
Key Takeaways
- Significant unmet need creates opportunities for disease-modifying RNA therapies.
- Collaborative development models can accelerate access to specialized RNA technologies and capabilities.
- Increasing competition is driving platform differentiation and pipeline expansion.
- Clinical progress will influence which RNA modalities and developers establish leadership in rare diseases.
Key Forces Shaping RNA Therapy Adoption in Rare Diseases
RNA therapeutics are gaining momentum as genetic insights, clinical validation, and personalized treatment approaches expand their potential across rare diseases. High treatment costs, evidence-generation challenges, and diagnostic delays continue to constrain broader adoption.
What Is Accelerating Growth?
- High Genetic Burden: Around 80% of rare diseases have a genetic origin, with many linked to single-gene mutations. RNA therapies can target disease-causing transcripts through approaches such as gene silencing and splice correction, supporting precision treatment for genetically defined patient populations.
- Clinical Validation of RNA Therapies: Of the 7,000–10,000 identified rare diseases, only about 5% have approved treatments. Regulatory approvals of RNA-based therapies are demonstrating their clinical potential and strengthening confidence in development pipelines targeting high-unmet-need rare diseases.
- Personalized RNA Therapeutics: The modular nature of ASOs is enabling N-of-1 and N-of-few therapies tailored to specific genetic mutations. Advances in genome sequencing and evolving regulatory pathways could accelerate development for ultra-rare diseases that are difficult to address through conventional drug development.
The Development Priority
Improving diagnostic pathways, evidence generation, manufacturing scalability, and patient identification will be critical to translating RNA innovation into accessible rare disease treatments.
RNA Modalities Advancing Rare Disease Therapeutics
RNA therapeutic development in rare diseases is progressing across siRNA, ASO, and mRNA platforms. Each modality offers a different therapeutic mechanism, delivery profile, and disease opportunity, influencing where clinical development is gaining momentum.
|
RNA Modalities and Innovators Advancing Rare Disease Treatment |
|||
|
RNA Modality |
Key Disease Focus |
What Is Driving Development |
Companies to Watch |
|
siRNA |
Hematologic, neuromuscular, metabolic, liver, immunologic, and central nervous system (CNS) disorders |
Tissue-targeted delivery, validated protein targets, strong genetic drivers, and well-defined molecular pathways are expanding RNAi applications beyond the liver. |
|
|
ASO |
Neurodegenerative and CNS, neuromuscular, ophthalmic, metabolic, respiratory, and ultra-rare genetic disorders |
Splice modulation, validated CNS delivery, localized administration, and flexible sequence-specific design support expansion across genetically defined diseases. |
|
|
mRNA |
Rare respiratory and metabolic disorders |
Inhaled delivery, protein restoration, and lipid nanoparticle-enabled targeting are opening opportunities where conventional protein replacement has limitations. |
· Moderna |
Where Will the Next Growth Opportunities in RNA Therapeutics Emerge?
The next phase of RNA therapeutics will depend on overcoming two persistent barriers: making RNA drug development faster and more precise, and delivering therapies effectively to difficult-to-reach tissues such as the CNS.
- AI-enabled RNA Therapy Development: Artificial intelligence (AI) and machine learning (ML) can improve RNA therapeutic development by supporting target discovery, sequence design, delivery optimization, and toxicity prediction. These capabilities are particularly relevant for rare diseases, where small patient populations and N-of-1 therapies require faster and more scalable development approaches.
Where companies can act:
- Applying AI/ML across target discovery, RNA sequence design, and delivery optimization
- Integrating multimodal and clinical datasets to improve rare disease target identification
- Using predictive models to optimize patient stratification, trial design, and safety assessment
- Building partnerships across biotechnology, diagnostics, hospitals, and research institutions
- Next-generation CNS Delivery Platforms: Delivery across the blood-brain barrier (BBB) remains a major challenge for RNA therapies targeting rare neurological diseases. Emerging approaches, including BBB-crossing delivery technologies, lipid-siRNA conjugates, brain shuttle systems, and engineered nanoparticles, could enable less invasive and more targeted CNS delivery.
Where companies can act:
- Investing in non-invasive, BBB-crossing RNA delivery platforms
- Developing delivery systems with greater stability, tissue specificity, and durability
- Partnering with specialized CNS delivery technology developers
- Prioritizing siRNA and ASO platforms demonstrating disease-modifying potential in genetically defined neurological disorders
Access the sample analysis to explore emerging RNA modalities.
What Will Shape the Future of RNA Therapies for Rare Diseases?
RNA therapeutics are poised to expand across genetically defined rare diseases as advances in RNA design, precision diagnostics, targeted delivery, and personalized treatment address current development barriers. Progress across siRNA, ASO, and mRNA platforms could extend RNA-based treatment into new tissues and disease areas, while AI has the potential to accelerate target identification and therapeutic development.
Frost & Sullivan Perspective: The convergence of AI-enabled drug development and tissue-specific delivery innovation could significantly expand the addressable rare disease landscape for RNA therapeutics. Companies that improve development efficiency, overcome delivery barriers, and align the right RNA modality with genetically defined patient populations will be better positioned to translate scientific progress into viable disease-modifying therapies.
Ready to Lead the Transformation?
- Schedule a Growth Strategy Dialog: Align your growth roadmap with Frost & Sullivan’s Visionary Growth Pipeline™ Dialog.
- Engage with Growth Experts: Co-design AI-enabled, data-driven operating models that scale industry-specific and commercial impact.
- Showcase Your Transformational Leadership: Position your organization as a transformation leader through Frost & Sullivan’s Transformational Growth Leadership platform.
- Join the Growth Council: Collaborate with industry leaders shaping the future of your ecosystem.
- Explore Best Practices Recognition: Be recognized for excellence in growth strategy, execution, and customer impact.
- Benchmark Your Industry Positioning on the Frost Radar™: Benchmark your growth performance and innovation strength against industry competitors.
- Tell Your Story: Accelerate awareness, engagement, and revenue growth through integrated brand and demand generation strategies.
Frequently Asked Questions
What are RNA therapies for rare diseases?
RNA therapies are treatments that target RNA to modify disease-causing biological processes. In rare diseases, modalities such as antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and messenger RNA (mRNA) can silence harmful genes, modify RNA processing, or restore missing proteins, enabling treatment closer to the underlying genetic cause.
Why are RNA therapies important for rare diseases?
Around 80% of rare diseases have a genetic origin, making them particularly relevant targets for RNA-based approaches. RNA therapies can be designed against specific genetic mutations or disease-causing transcripts, creating opportunities for disease-modifying and precision treatments where conventional therapeutic options are limited.
What is the difference between ASO, siRNA, and mRNA therapies?
ASOs bind to specific RNA sequences to alter RNA processing or protein production. siRNA therapies use RNA interference to silence disease-associated genes by degrading targeted messenger RNA. mRNA therapies deliver genetic instructions that enable cells to produce therapeutic proteins. The appropriate modality depends on the disease mechanism, target tissue, and required therapeutic effect.
Which rare diseases are being targeted by RNA therapies?
RNA therapies are being developed across neuromuscular, neurodegenerative, hematologic, metabolic, ophthalmic, respiratory, hepatic, and other genetically defined rare diseases. Clinical development varies by modality, with ASOs showing significant activity in neurological and neuromuscular disorders, while siRNA and mRNA platforms are expanding into additional tissues and disease areas.
What are the biggest challenges facing RNA therapies for rare diseases?
Major challenges include high treatment and manufacturing costs, tissue-specific delivery, blood-brain barrier penetration, small patient populations, diagnostic delays, and limited real-world evidence. Overcoming these barriers will be important for expanding clinical development and patient access.
How could AI accelerate RNA therapy development?
Artificial intelligence (AI) and machine learning (ML) can support target discovery, RNA sequence design, toxicity prediction, delivery optimization, patient stratification, and clinical trial design. These capabilities could shorten development timelines and support personalized RNA therapies for ultra-rare patient populations.
What will drive the future of RNA therapeutics for rare diseases?
Future progress will depend on advances in precision diagnostics, AI-enabled drug development, tissue-specific delivery, biomarker-driven patient selection, and personalized RNA design. Innovation in blood-brain barrier-crossing technologies could also expand RNA therapeutics into rare neurological and central nervous system (CNS) disorders.
